Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Cash & Equivalents (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Cash & Equivalents data on record, last reported at $8.9 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 68.62% year-over-year to $8.9 million; the TTM value through Sep 2025 reached $8.9 million, down 68.62%, while the annual FY2024 figure was $46.1 million, 82.83% up from the prior year.
  • Cash & Equivalents reached $8.9 million in Q3 2025 per GOSS's latest filing, down from $26.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $112.0 million in Q4 2022 and bottomed at $3.8 million in Q2 2023.
  • Average Cash & Equivalents over 4 years is $44.8 million, with a median of $32.8 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: tumbled 95.97% in 2023, then skyrocketed 2186.24% in 2024.
  • A 4-year view of Cash & Equivalents shows it stood at $112.0 million in 2022, then tumbled by 77.49% to $25.2 million in 2023, then soared by 82.83% to $46.1 million in 2024, then crashed by 80.61% to $8.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $8.9 million in Q3 2025, $26.3 million in Q2 2025, and $29.0 million in Q1 2025.